期刊
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
卷 20, 期 2, 页码 240-245出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00004714-200004000-00018
关键词
-
It has been suggested that inclusion of a placebo treatment arm in controlled clinical trials might bias the selection of study subjects. Presumably, patients in the placebo-controlled studies are more stable, but there are no data available to support such an assumption. The authors tested the hypothesis in a set of randomized trials of neuroleptics in treating schizophrenia by comparing placebo-controlled (PCTs) and comparator-controlled trials (CCTs) in terms of basic patient characteristics. The results, based on a total of 296 studies, showed that the patients in BCTs, compared with those in CCTs, mere older (p < 0.002), had a longer duration of illness (p < 0.001), and a loa er initial symptom severity (p < 0.02). No difference was found in the number of subjects per treatment arm or in the proportion of female subjects. However, investigation of studies which used same-gender study subjects revealed that female-only populations mere more likely to be tested in PCTs (p < 0.03) than in CCTs, To investigate current trends in psychopharmacologic research, the authors tested separately a subset of trials of new atypical antipsychotics. The results indicated a significantly smaller number of females participating in the latest PCTs (p < 0.0003). Moreover, our findings suggest that the characteristics of patients in the current controlled trials are rather uniform; thus, the generalizability of new study findings for certain groups of patients,vith schizophrenia (e.g., with early or late onset or brief duration of illness) may be compromised.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据